Emerging Infections and Global Outbreaks: Implications for HIV and Infectious Disease Care in the US

Assessment of Needs

Emerging infectious diseases and global outbreaks continue to shape clinical practice, with important implications for the care of people with HIV. Increasing international travel, climate change, antimicrobial resistance, and zoonotic diseases such as ebola have heightened the risk of rapid disease spread and evolving epidemiology. This webinar will review recent and emerging global infectious threats, their relevance to HIV and infectious disease care, and practical considerations for diagnosis, prevention, and clinical management in US settings.

Learning Objectives

At the completion of this activity, participants will be able to:

• Describe key emerging infections and global outbreaks with relevance to HIV and infectious disease care in the US
• Describe the implications of emerging infectious threats for the prevention, diagnosis, and management in people with HIV
• List evidence-based strategies to identify and respond to emerging infectious diseases in clinical practice

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, July 14, 2026, 10:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Chin-Hong reported no financial relationships with ineligible companies. (Updated June 3, 2026)

Moderator

Dr Armstrong reported receiving consulting or advisor fees from L’Oreal Dermatologic Beauty. (Updated May 29, 2026)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies. (Updated May 29, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated April 28, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/